Drug X which inhibit the binding of RANKL to its receptor (RANK) in osteoporosis:
**Core Concept**
The underlying principle being tested is the **pathophysiology of osteoporosis** and the **mechanism of bone resorption**. Osteoporosis is characterized by an imbalance between bone formation and resorption, with **RANKL (Receptor Activator of NF-κB Ligand)** playing a crucial role in the activation of osteoclasts, which are responsible for bone resorption.
**Why the Correct Answer is Right**
The correct answer is a drug that inhibits the binding of **RANKL to its receptor RANK**, thereby reducing osteoclast activation and bone resorption. This mechanism is key to treating osteoporosis, as it helps to restore the balance between bone formation and resorption. **Denosumab** is an example of such a drug, which is a **monoclonal antibody** that targets **RANKL**.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it does not specifically target the RANKL-RANK pathway.
**Option B:** Incorrect as it is not related to the RANKL-RANK pathway.
**Option C:** Incorrect because it is not a known inhibitor of RANKL binding to its receptor.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that **denosumab** is used in the treatment of **osteoporosis**, particularly in patients with a high risk of fracture. It is also used in the treatment of **bone metastases** and **giant cell tumor of bone**.
**Correct Answer:** D. Denosumab.